Alfred Hospital and Monash University, Melbourne, Vic., Australia.
Department of Clinical Haematology, Austin Health and Olivia Newton John Cancer Research Institute, Melbourne, Vic., Australia.
Br J Haematol. 2021 Mar;192(6):1026-1030. doi: 10.1111/bjh.16722. Epub 2020 May 26.
Based on promising results in older adults with acute myeloid leukaemia (AML), we treated patients with NPM1 measurable residual disease (MRD) using off-label venetoclax in combination with low-dose cytarabine or azacitidine. Twelve consecutive patients were retrospectively identified, including five with molecular persistence and seven with molecular relapse/progression. All patients with molecular persistence achieved durable molecular complete remission (CR ) without transplantation. Six of seven patients with molecular relapse/progression achieved CR after 1-2 cycles of venetoclax. This paper highlights the promising efficacy of venetoclax-based therapy to reduce the relapse risk in patients with persistent or rising NPM1 MRD.
基于在老年急性髓系白血病（AML）患者中取得的有希望的结果，我们使用非适应证的维奈托克联合低剂量阿糖胞苷或阿扎胞苷治疗伴有 NPM1 可测量残留病（MRD）的患者。回顾性确定了 12 例连续患者，包括 5 例分子持续存在和 7 例分子复发/进展。所有分子持续存在的患者均在未进行移植的情况下实现了持久的分子完全缓解（CR）。7 例分子复发/进展患者中的 6 例在接受 1-2 个周期的维奈托克治疗后获得 CR。本文强调了基于维奈托克的治疗方案在降低持续性或升高的 NPM1 MRD 患者的复发风险方面具有良好的疗效。
